Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
155 Tumors Trials near New York, NY
Power is an online platform that helps thousands of Tumors patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerCell Therapy for Sarcoma
New York, New York
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:10+
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Prior Malignancy, Others
Must Not Be Taking:Steroids, Immunosuppressives
7 Participants Needed
SAR444200 + Atezolizumab for Cancer
New York, New York
This trial is testing a new drug called SAR444200, either alone or with other cancer treatments. It targets adults with advanced cancer who have already received other treatments. The study will check if the drug is safe, how it behaves in the body, and if it helps treat cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Cardiovascular Disease, HIV, Others
Must Not Be Taking:Immunosuppressants, Anti-PD1/PD-L1
33 Participants Needed
LY3537021 for Nausea and Vomiting from Chemotherapy
New York, New York
The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Uncontrolled Diabetes, Cardiac Conditions, Others
Must Not Be Taking:Antiemetics, GIP, GLP-1
204 Participants Needed
Alectinib for Pediatric Brain Cancer
New York, New York
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:< 17
Key Eligibility Criteria
Disqualifiers:Substance Abuse, Organ Transplant, HIV, Others
Must Not Be Taking:Alk Inhibitors
42 Participants Needed
TSR-022 for Advanced Cancer
New York, New York
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Uncontrolled CNS Metastases, Active Infection, Autoimmune Disease, Others
Must Be Taking:Antivirals
475 Participants Needed
GSK3745417 for Cancer
New York, New York
This trial is testing a new drug, GSK3745417, alone and with another drug, dostarlimab, in patients whose solid tumors have not responded to other treatments or have returned. The goal is to find the best dose and see if these drugs can help shrink the tumors. Dostarlimab is recently approved for the treatment of various cancers, including certain types of endometrial cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
97 Participants Needed
Pembrolizumab for Fast-Growing Cancers
New York, New York
This study will be looking at whether MK-3475 (pembrolizumab) is effective (anti-tumor activity) and safe in patients with MSI (Microsatellite Unstable) negative cancer with a mutator phenotype.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
12 Participants Needed
SRT vs GammaTile Therapy for Brain Tumor
New York, New York
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Leptomeningeal Metastasis, Others
230 Participants Needed
CHS-114 + Toripalimab for Cancer
New York, New York
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Prior Malignancy, CNS Metastases, Others
Must Not Be Taking:Corticosteroids, CCR8 Antibodies
154 Participants Needed
LY4050784 for Advanced Cancer
New York, New York
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:SMARCA2 Alterations, CNS Involvement, Cardiovascular Disease, Others
Must Not Be Taking:SMARCA2 Inhibitors
340 Participants Needed
RLY-5836 for Advanced Breast Cancer
New York, New York
This trial is testing a new drug called RLY-5836 in patients with advanced cancers that have a PIK3CA mutation. The drug aims to block this mutation to slow down tumor growth. The study will determine how safe and effective the drug is.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Diabetes, Others
Must Be Taking:GnRH Agonists
265 Participants Needed
BGB-3245 for Solid Cancer
New York, New York
This trial is testing a new drug called BGB-3245 to see if it can help patients with advanced or treatment-resistant cancers by stopping the cancer cells from growing.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Severe Disease, Cardiac Disease, CNS Metastases, HIV, Others
Must Not Be Taking:Chemotherapy, Immunotherapy
110 Participants Needed
Histotripsy for Kidney Cancer
New York, New York
The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22+
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active Cancers, Dialysis, Others
Must Not Be Taking:Aspirin, NSAIDS, Anticoagulants
67 Participants Needed
177Lu-DOTA-TATE + Octreotide LAR for Neuroendocrine Tumors
New York, New York
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12 - 100
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Major Surgery, Others
Must Be Taking:Somatostatin Analogues
240 Participants Needed
RYZ101 for Neuroendocrine Tumors
New York, New York
This trial tests RYZ101, a new drug, in patients with advanced GEP-NETs that haven't responded to previous treatments. The drug aims to target specific receptors on the tumor cells to stop their growth.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Resistant Hypertension, Uncontrolled Diabetes, Others
Must Not Be Taking:High-dose Glucocorticoids
288 Participants Needed
PRRT for Neuroendocrine Tumors
New York, New York
This trial is testing a new treatment that uses a radioactive drug to target and kill specific cancer cells in patients with certain types of neuroendocrine tumors. It aims to see if this method is more effective and safer than current treatments.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Other Malignancies, Serious Diseases, Organ Dysfunction, Others
259 Participants Needed
Selumetinib + Vinblastine for Low-Grade Glioma
New York, New York
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2 - 25
Key Eligibility Criteria
Disqualifiers:Concurrent Malignancy, Diffuse Intrinsic Pontine Tumors, Serious Medical Conditions, Others
Must Not Be Taking:CYP3A4 Agents
300 Participants Needed
Radiation Therapy vs Observation for Meningioma
Brooklyn, New York
This trial studies if radiation therapy helps prevent the return of grade II meningioma after surgery. Radiation therapy uses powerful x-rays to destroy any leftover cancer cells. The goal is to see if this improves patient outcomes compared to just monitoring them. Radiation therapy has shown success in stabilizing tumor growth and reducing recurrence risk.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Metastatic Meningioma, Prior Invasive Malignancy, Others
163 Participants Needed
Various Treatments for Wilms Tumor
New York, New York
This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:< 30
Key Eligibility Criteria
Disqualifiers:Stage V Wilms, Uncontrolled Illness, Others
Must Not Be Taking:Concurrent Chemotherapy
1656 Participants Needed
R-DXd for Ovarian Cancer
New York, New York
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Cardiovascular Disease, ILD/pneumonitis, Others
Must Not Be Taking:Steroids, Anticonvulsants, Chloroquine
710 Participants Needed
Why Other Patients Applied
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
DAY101 vs. Chemotherapy for Pediatric Brain Cancer
New York, New York
This trial is testing tovorafenib, a medication given alone, in children with a specific type of brain tumor. The drug works by blocking a protein that helps cancer cells grow.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:< 25
Key Eligibility Criteria
Disqualifiers:Schwannoma, NF-1, NF-2, Others
Must Not Be Taking:Chemotherapy, Targeted Therapy
400 Participants Needed
Octreotide Depot for Neuroendocrine Tumors
New York, New York
This trial is testing CAM2029, a new treatment for patients with advanced GEP-NET, a type of cancer. The goal is to see if CAM2029 works better and is safer than current treatments. If patients' cancer worsens, they can receive more intensive treatment with CAM2029.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Refractory Carcinoid Symptoms, Others
Must Not Be Taking:MTOR Inhibitors, Chemotherapy
332 Participants Needed
Durvalumab + FLOT for Gastric Cancer
New York, New York
This trial is testing whether adding durvalumab to a standard chemotherapy mix around the time of surgery can help patients with stomach or gastroesophageal cancer. Durvalumab helps the immune system fight cancer, while the chemotherapy drugs kill cancer cells.
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Metastasis, Adenosquamous Carcinoma, Transplant, Others
Must Not Be Taking:Immunosuppressants
957 Participants Needed
Vorasidenib for Glioma
New York, New York
This trial is testing an oral medication called vorasidenib in patients with a specific type of brain tumor that has a genetic mutation. The drug aims to block proteins that help the tumor grow, potentially slowing or stopping its growth.
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12+
Key Eligibility Criteria
Disqualifiers:Prior Anticancer Therapy, High-risk Features
Must Not Be Taking:IDH Inhibitors
331 Participants Needed
Cabozantinib for Pancreatic Neuroendocrine Tumors
New York, New York
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Congestive Heart Failure, Cardiac Arrhythmia, Hypertension, Others
Must Not Be Taking:Warfarin, Strong CYP3A4 Inhibitors
298 Participants Needed
Radiation Therapy + Temozolomide for Brain Tumor
New York, New York
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with or without temozolomide in treating patients with low-grade glioma.
PURPOSE: This randomized phase III trial is studying radiation therapy so see how well it works when given together with or without temozolomide in treating patients with low-grade glioma.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Other Malignancy, Uncontrolled Infection, HIV, Others
540 Participants Needed
Radiation and Temozolomide vs. PCV Chemotherapy for Brain Tumor
New York, New York
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Nursing, HIV, Active Infection, Others
Must Not Be Taking:Retroviral Therapy
305 Participants Needed
Temozolomide + Radiation Therapy for Brain Cancer
New York, New York
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known whether giving temozolomide during and/or after radiation therapy is more effective than radiation therapy alone in treating anaplastic glioma.
PURPOSE: This randomized phase III trial is studying giving temozolomide during and/or after radiation therapy to see how well it works compared to radiation therapy alone in treating patients with anaplastic glioma.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B/C, Prior Chemotherapy, Others
Must Not Be Taking:Chemotherapy, Anticancer Agents
751 Participants Needed
Chemotherapy + Radiation for Medulloblastoma
New York, New York
This phase III trial studies different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma. Chemotherapy drugs, such as vincristine sulfate, cisplatin, cyclophosphamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Carboplatin may make tumor cells more sensitive to radiation therapy. It is not yet known which chemotherapy and radiation therapy regimen is more effective in treating brain tumors.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:3 - 22
Key Eligibility Criteria
Disqualifiers:Previous Chemotherapy, Radiation Therapy, M4 Disease, Others
Must Not Be Taking:Azole Antifungals, Rifampin, Phenytoin, Others
379 Participants Needed
Chemotherapy + Stem Cell Transplant for Brain Cancer
New York, New York
This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma when given before additional intense chemotherapy followed by peripheral blood stem cell rescue. It is not yet known which combination chemotherapy regimen is more effective when given before a peripheral stem cell transplant in treating supratentorial primitive neuroectodermal tumors or medulloblastoma.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:< 2
Key Eligibility Criteria
Disqualifiers:Radiation Therapy, Chemotherapy, Others
Must Not Be Taking:Anticonvulsants, Azole Antifungals
91 Participants Needed
Know someone looking for new options?
Spread the word